title: How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
authors.affiliation: Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA, Australia.
authors.forename: David M
authors.initials: DM
authors.lastname: Ross
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Hughes
mesh_terms: D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D025202:Molecular Diagnostic Techniques; D018365:Neoplasm, Residual / Q000175:diagnosis*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate